It's Official: Novartis SMA Gene Therapy Zolgensma Is World's Most Expensive Drug
Executive Summary
The total cost of Zolgensma is more than $2m – in line with estimates – or $425,000 annually for five years if payers choose an annuity-like payment plan. Novartis is also negotiating value-based reimbursement agreements for infants treated with the one-time infusion.
You may also be interested in...
Roche’s Evrysdi Approved For SMA, Priced Below Competitors
Risdiplam’s efficacy across two clinical trials and oral dosing made it a credible threat before its US FDA approval, but its weight-based pricing falls below Biogen’s Spinraza and Novartis’s Zolgensma.
One Way To Get Ahead: Biogen To Test Spinraza Given After Novartis’s Zolgensma
Biogen said some spinal muscular atrophy patients are currently being treated with Spinraza after receiving the Novartis gene therapy – its main competitor – so it will start a study of the risk/benefit in 2021.
Gene Therapies Will Be A Bigger Cost Issue In 2021, PwC Predicts
The expected launch of BioMarin's Roctavian for hemophilia A is expected to heighten the profile of expensive gene therapies on payers' radar. Specialty drug costs are expected to continue to grow in 2021.